Sun Pharma announced today that the U.S. Food and Drug Administration (FDA) has approved ILUMYA™ (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are... read more
Sun Pharma announced today that the U.S. Food and Drug Administration (FDA) has approved ILUMYA™ (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are... read more
Little more than 24 hours after announcing a proposed public offering of 9,000,000 shares of common stock, Proteostasis Therapeutics announced that it is withdrawing the offering. The reason given... read more
Inovio announced today that it closed an agreement providing ApolloBio Corp. (NEEQ:430187) with the exclusive right to develop, manufacture and commercialize VGX-3100, Inovio’s DNA immunotherapy... read more
Cotinga announced that it has submitted an updated clinical package to regulatory authorities to expand its ongoing Phase 1 trial of COTI-2. The protocol amendment will expand the clinical trial... read more
S2516: Alternatives to Opioids (ALTO) in the Emergency Department Act
This bill was introduced by Senator Corey Booker (D-NJ) on 3/7/2018 and cosponsored by Senators... read more